Cedric Francois Sells 6,247 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,247 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $179,288.90. Following the completion of the transaction, the chief executive officer now owns 307,415 shares of the company’s stock, valued at $8,822,810.50. The trade was a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Apellis Pharmaceuticals Price Performance

Shares of APLS stock opened at $29.03 on Thursday. The stock’s fifty day moving average is $31.86 and its 200-day moving average is $33.45. The stock has a market capitalization of $3.61 billion, a PE ratio of -14.30 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.17) EPS. Equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in APLS. Wolverine Asset Management LLC bought a new position in Apellis Pharmaceuticals in the third quarter valued at about $27,000. True Wealth Design LLC bought a new position in Apellis Pharmaceuticals in the third quarter valued at about $27,000. Capital Performance Advisors LLP bought a new position in Apellis Pharmaceuticals in the third quarter valued at about $56,000. KBC Group NV lifted its stake in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after buying an additional 679 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after buying an additional 781 shares during the period. Institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

APLS has been the subject of a number of recent research reports. Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday. Piper Sandler lowered their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target on the stock. in a research report on Tuesday, December 17th. Finally, Bank of America lowered their price target on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $46.65.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).